Alzamend Registers 39.4M Ault Lending Resale Shares — 8x Current Share Count
ALZN sits 32% above its 52-week low of $0.84 on light trading volume (0.3× avg).
Summary
Alzamend registered up to 39,355,322 shares for resale by Ault Lending, the holder of its Series D convertible preferred — roughly eight times its 4.8 million shares outstanding. The company gets no proceeds; the filing makes a deeply dilutive, price-floating conversion overhang tradable.
Key Events · Financing and Capital Events · ALZN
-
39.4M-Share Resale Shelf Filed
An S-3 registers up to 39,355,322 conversion shares for Ault Lending, versus 4,825,723 shares outstanding as of November 17, 2026 — roughly 8.2x the current share count if fully converted.
-
Floating 20% Discount Conversion
Each $1,050 Stated Value Preferred Share converts at the greater of a $0.2668 Floor Price and 80% of the lowest five-day closing bid, capped at $2.00 — so a falling stock price mechanically increases the share count issued.
-
Nasdaq Cap Requires Shareholder Vote
Issuance is capped at 19.99% of shares outstanding on the Execution Date, or 964,662 shares, until stockholders approve; the company must file a preliminary proxy within 15 days and a definitive proxy within 45 days of November 10, 2026.
-
$2.5M Second Tranche Tied to Effectiveness
Ault has already bought 7,500 Preferred Shares; the remaining $2.5 million closes on the tenth business day after this registration is declared effective, with a December 31, 2026 effectiveness deadline and 2% monthly liquidated damages capped at 15%.
Analysis · ALZN · Life Sciences
This S-3 makes the Ault Lending convertible preferred overhang tradable. No company shares are sold here and no proceeds are received; Ault can resell up to 39,355,322 conversion shares against just 4,825,723 shares outstanding today. Because the conversion price floats at 80% of the lowest five-day closing bid (floor $0.2668, cap $2.00), the lower the stock falls the more shares Ault receives — a classic death-spiral structure. Near-term issuance is limited by a 4.99% ownership blocker and the Nasdaq 19.99% cap (964,662 shares), but the company must hold a special meeting to lift that cap, and the remaining $2.5 million second tranche only closes after this registration goes effective. Set against a going-concern warning and an FDA rejection of the bipolar trial design disclosed the same day, this document captures both the financing lifeline and the dilution risk.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.84 to $2.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.